Cancer Treatment Today

1. Hereditary testing: The most recent review by Tuffaha et al concludes: “While genetic testing in prostate cancer is routinely recommended and numerous guidelines exist, there is still considerable lack of consensus regarding who should be tested and how they should be tested. Further evidence is needed to inform value-based genetic testing strategies for implementation in practice.”

NCCN definitively recommends hereditary testing for two groups:
1.For individuals
of Ashkenazi Jewish descent, complete gene panel analysis
including specific AJ founder mutations should be considered
based on family history; testing limited to AJ founder testing may
be appropriate for families segregating known mutations, or in
population screening in which a negative test is followed by more
complete testing depending on personal and/or family history.
2.There may also be a role for multigene testing in individuals
who have tested negative for a single syndrome, but whose
personal or family history remains suggestive of an inherited
susceptibility
However, in the prostate guidelines, NCCN says ( P. PROSC-1), it says: “Germline testing should be considered in appropriate individuals where it is likely to impact the prostate cancer treatment and clinical trial
options, management of risk of other cancers, and/or potential risk of cancer in family members.”

2. NGS testing – NCCN says ( P. PROSC-1), it says: “Germline testing should be considered in appropriate individuals where it is likely to impact the prostate cancer treatment and clinical trial
options, management of risk of other cancers, and/or potential risk of cancer in family members.”

Tuffaha, H., Edmunds, K., Fairbairn, D. et al. Guidelines for genetic testing in prostate cancer: a scoping review. Prostate Cancer Prostatic Dis 27, 594–603 (2024). https://doi.org/10.1038/s41391-023-00676-0

NCCN Prostate Cancer, 2025

NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate